Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nuvance (Immunex).

R W Lange1

  • 1Department of Environmental Occupational Health, University of Pittsburgh, RIDC Park, Pittsburgh, PA 15238, USA. lange@pop.pitt.edu

Idrugs : the Investigational Drugs Journal
|September 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Importance of inflammatory and immune components in a mouse model of airway reactivity to toluene diisocyanate (TDI).

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2001
Same author

Rapid reduction of intracellular glutathione in human bronchial epithelial cells exposed to occupational levels of toluene diisocyanate.

Toxicological sciences : an official journal of the Society of Toxicology·2001
Same author

Intracellular S-glutathionyl adducts in murine lung and human bronchoepithelial cells after exposure to diisocyanatotoluene.

Chemical research in toxicology·1999
Same author

Toluene diisocyanate colocalizes with tubulin on cilia of differentiated human airway epithelial cells.

Toxicological sciences : an official journal of the Society of Toxicology·1999
Same author

Altered alveolar macrophage function in calorie-restricted rats.

American journal of respiratory cell and molecular biology·1998
Same author

Antioxidants attenuate anthralin-induced skin inflammation in BALB/c mice: role of specific proinflammatory cytokines.

Journal of leukocyte biology·1998
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Nuvance, a genetically-engineered soluble interleukin-4 receptor (IL-4R), is in phase II trials for allergic asthma treatment. This IL-4R therapy also shows potential for transplant rejection, graft versus host disease, and infectious diseases.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Allergic asthma involves complex immune responses mediated by interleukin-4 (IL-4).
  • Targeting the IL-4 pathway is a key strategy for managing allergic inflammation.

Purpose of the Study:

  • To evaluate the safety and efficacy of genetically-engineered soluble interleukin-4 receptor (IL-4R) as a nebulized therapy.
  • To explore the therapeutic potential of IL-4R in allergic asthma and other immune-related conditions.

Main Methods:

  • Worldwide phase II clinical trials are being conducted.
  • Nuvance (genetically-engineered soluble IL-4R) is administered as a nebulized liquid.

Main Results:

  • Nuvance is under investigation for its potential to treat allergic asthma.

Related Experiment Videos

  • Preliminary findings suggest broader applications for IL-4R in immune-mediated diseases.

    • Conclusions:

    • Nebulized IL-4R (Nuvance) represents a promising therapeutic candidate for allergic asthma.
    • The IL-4R pathway's modulation holds potential for treating organ transplant rejection, graft versus host disease, allergies, and infectious diseases.